[an error occurred while processing this directive]
C&EN logo The Newsmagazine of the Chemical World
Home Current Issue ChemJobs Join ACS
Support
Latest News
Business
Government & Policy
Science/Technology
Careers and Employment
ACS News
topics
   
Support
 
Support
How to log in
Contact Us
Site Map
   
About C&EN
About the Magazine
How to Subscribe
How to Advertise
Chemcyclopedia

Latest News RSS Feed

latest news RSS feedWhat is this?

   
Join ACS
Join ACS
  Latest News  
  February 28,  2005
Volume 83, Number 9
p. 11
 

PHARMACEUTICALS

  Novartis Tops Generics Market
Swiss company's purchase of two firms will vault it into global leadership
 

PATRICIA SHORT
   
 
 
8309NOTW1_Lek.tif
FAMILY TIES Hexal and Eon Labs will become part of a generics business that includes this plant operated in Slovenia by Lek Pharmaceuticals.

LEK PHOTO

With acquisitions valued at roughly $8.3 billion, Novartis is moving into the top spot in the worldwide generic drug industry, which is currently undergoing a flurry of acquisitions and alliances.

Novartis has agreed to acquire the privately held German firm Hexal and a 67.7% share of Eon Labs, a publicly traded U.S. firm that shares owners with Hexal, for about $7.3 billion. Moreover, Novartis will launch a tender offer to acquire the remaining 34.6% of Eon for $31 per share, adding nearly another $1 billion to the price tag.

The acquired businesses will be integrated into Novartis' Sandoz division, which specializes in generics. Sandoz would have pro forma 2004 sales of $5.1 billion, a portfolio of more than 600 active ingredients in more than 5,000 dosage forms, and more than 20,000 employees. That will edge Sandoz in front of the current market leader, Israel's Teva Pharmaceuticals, which had sales last year of $4.8 billion.

Novartis decided several years ago to go against the grain of the R&D-based drug industry and build up its generics business, which now accounts for about 11% of its sales. The company says generics complement its prescription and over-the-counter products by providing leverage in manufacturing and in dealing with large drug purchasers.

In one of its first deals to support the strategy, Novartis acquired Slovenian generics producer Lek Pharmaceuticals in 2002. And last August, it completed the purchase of Canada's Sabex Holdings for $565 million.

In 2004, Sandoz itself had operating profits of $235 million, down 50% from the previous year, on sales of $3.1 billion, up 5% from 2003. The company blames the profitability decline on pricing pressures in Germany, where it has a small market share, and in the U.S. The Hexal/Eon deal aims at addressing the weaknesses in both those markets.

"The combination of Sandoz with Hexal and Eon Labs offers an outstanding opportunity to capitalize on the unique strengths of each company," Sandoz CEO Andreas Rummelt says. "Together, we will create a highly competitive leader with a comprehensive global presence and the expertise necessary for success in the rapidly changing generics market."

8309NOTW1_Ruem.tif.cxd
Rummelt

NOVARTIS PHOTO

However, some analysts question whether Novartis will be able to accomplish its aim of reducing pricing pressure.

"I am a little bit skeptical about the strategy, especially about investing in the two markets--Germany and the U.S.--where there are structural problems," says Birgit Kulhoff, a securities analyst with investment bank Sal. Oppenheim. "Will they be compounding the pricing pressure? Novartis says it won't, but I have my doubts." Kulhoff says the company has good arguments for the acquisition, but she sees them taking a long time to pay off.

Other generics deals are in the offing. One of the leading U.S. generics makers, Mylan Laboratories, is attempting to acquire the branded drugmaker King Pharmaceuticals, although the deal has hit roadblocks since it was announced last summer.

And last week, the Croatian firm Pliva agreed to cooperate on development and future marketing of its two most advanced biogenerics--erythropoietin and granulocyte colony stimulating factor--with Australia's Mayne Pharma. Pliva aims to become one of the world's top five generics companies within the next four years. Its annual sales are now close to $1 billion.

 
     
  Chemical & Engineering News
ISSN 0009-2347
Copyright © 2005
 


Related Story
Novartis To Acquire Sabex
[C&EN, June 14,  2004]
 
E-mail this article
to a friend
Print this article
E-mail the editor